Home
-
Systemic Lupus Erythematosus (SLE) is an incurable autoimmune disease that can result in significant disease complications such as strokes, end-stage kidney failure and premature death.
Compared to other autoimmune diseases, there has been a lack of new drug approvals for treating SLE, in part due to issues with the current outcome measures used in SLE clinical trials.
The global TRM-SLE Taskforce, established in 2022, is developing a new clinical trial outcome measure to overcome the issues with current clinical trial outcome measures.
This site provides an overview of work towards development of the Treatment Response Measure for SLE (TRM-SLE) outcome measure.
The TRM-SLE project is managed by Clinical Sciences at Monash Health.
Project overview
TRM-SLE is a global collaboration of more than 80 SLE clinician-scientists, patient representatives, industry partners, and regulatory and metrology experts.
Want to know more about the TRM-SLE project and the TRM-SLE Taskforce?
Review our project overview to find out more.
For clinicians and researchers
The TRM-SLE project is developing a new clinical outcome assessment suitable for implementation in a primary efficacy endpoint in SLE clinical trials.
For patients
The TRM-SLE Taskforce is aiming to capture improvements in SLE that are meaningful to patients and their clinicians.
For industry
Monash University has established a multi-institutional agreement with its industry partners that governs conduct of the TRM-SLE project.
-
TRM-SLE news
-
Partners
 |  |  |  |  |
 |  |  |  |  |
 |  |  |  |  |
-
